After evidence of the potential therapeutic relevance of RANKL/RANK pathway blockade beyond cancer therapy-induced bone loss and BM management, several ongoing and completed clinical trials aimed to evaluate the anti-tumor effect of denosumab in BCa prevention and neoadjuvant treatment. Here, TNFSF11 is linked to cancer.